Your session is about to expire
← Back to Search
ADT + Pembrolizumab for Salivary Gland Cancer
Study Summary
This trial is testing a new treatment for salivary gland cancer that has spread or come back and is not able to be treated with surgery or radiation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My salivary gland cancer is confirmed to be androgen receptor-positive.I am currently being treated for an infection.My organ functions are within normal ranges as per recent tests.I haven't needed systemic treatment for an autoimmune disease in the last 2 years.My salivary gland cancer cannot be cured with surgery or radiation.I had palliative radiotherapy within the last week and have recovered from side effects.I have not received a live vaccine in the last 28 days.My condition worsened after my last treatment.My brain metastases are stable, and I haven't needed steroids for 14 days.I have undergone hormone therapy for cancer, including treatments like orchiectomy or medications such as abiraterone.I have another cancer besides skin or in situ cancers that needed treatment in the last 2 years.My blood clotting tests are within normal limits, or if I'm on blood thinners, they're in the therapeutic range.I have recovered from previous cancer treatment side effects, except for hair loss.My kidney function, measured by creatinine or GFR, is within the required range.I am not pregnant and can prove it with a test taken in the last 3 days.My liver function tests are within the required range.I agree to use birth control and not donate sperm for 8 months after my last treatment dose.I've had treatments like chemotherapy or surgery for cancer, but not anti-androgen therapy or immune checkpoint inhibitors.I have received a transplant from another person.I haven't had any cancer treatment or experimental drugs in the last 14 days.I am 18 years old or older.I have or had lung inflammation not caused by infection, treated with steroids.I am not on high-dose steroids or other drugs that weaken my immune system.I have been treated with specific immune therapy drugs before.I have been diagnosed with HIV.I have an active tuberculosis infection.My cancer can be measured by scans taken within the last 28 days.I have been mostly active and able to carry on all pre-disease activities without restriction recently.I am of childbearing age and have a positive pregnancy test.I can understand and follow the study's procedures for its duration.You have had a severe allergic reaction to pembrolizumab or any of its ingredients.
- Group 1: Goserelin Acetate + Pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any remaining slots for participants in this medical test?
"The available information on clinicaltrials.gov confirms the recruitment status of this trial, which was first made accessible to potential participants on May 30th 2019 and recently updated on September 22nd 2022."
Has this trial been implemented in any North American locales?
"Northwestern University Feinberg School of Medicine, located in Chicago, Illinois; the Masonic Cancer Center at The Univeristy of Minnesota in Minneapolis; and the Univeristy of Maryland based out of Baltimore are three primary sites for this trial. An additional 7 medical centres round out its locations."
Has Pembrolizumab been tested as part of any other medical experiments?
"The first evaluation of pembrolizumab occurred in 2000 at Centre de Recherche Clinique du CHUS. As of now, 340 clinical trials have been completed and 1027 are still recruiting participants - with a significant portion based out of Chicago, Illinois."
How many individuals have joined the trial to date?
"Affirmative. The information on clinicaltrials.gov indicates that this research is currently recruiting participants; the trial was first announced on May 30th 2019, and recently updated on September 22nd 2022. There are 20 openings across 7 medical locations."
Has Pembrolizumab received governmental authorization for therapeutic use?
"While safety data is present, the efficacy of pemrolizumab has yet to be established. This leads us at Power to rate its respective level of security as a 2 on our scale."
Does this research endeavor offer any fresh insights?
"Ever since it was first studied by AstraZeneca in 2000, Pembrolizumab has been extensively researched. After the initial trial involving 600 participants was conducted, clinical trials of pembrolizumab were approved for phase 3 drug testing and now 1027 studies are underway across 65 countries and 3157 cities."
Share this study with friends
Copy Link
Messenger